The conjugate vaccine comprises microbial capsular polysaccharide with a protein to boost immunogenicity and protect beside invasive diseases. It is also known as the immunogen conjugate vaccines. It combines a pathetic antigen with a robust antigen by which the protected system has a stronger response to the pathetic antigen. It includes linking external coats (polysaccharide) to proteins (toxins). It reduces the vaccine serotypes in the nasopharynx and reduces the local pneumococci extent which can cause Acute Otitis Media (AOM) or sinusitis to nearby mucosa. Some of the essential features are longer lasting protection, the creation of herd immunity improved immune & memory response and protection of infants & toddlers etc. All these vaccines are approved by the Food & Drug Administration (FDA).
Some of the major side-effects associated with the conjugate vaccine are joint pain or muscle pain, low fever, vomiting, redness, swelling, headache, tired feeling, diarrhea, irritability, fussiness, loss of appetite and drowsiness.
According to study, “Asia-Pacific Conjugate Vaccine Market (2018-2023)” some of the major companies that are currently working in the Asia-Pacific conjugate vaccine market are GlaxoSmithKline Plc., Fablife, Merck & Co. Inc., Green Signal Bio Pharma Limited, MedImmune LLC, Biological E. Limited, Johnson and Johnson, Sanofi Pasteur,Emergent BioSolutions Inc., Bharat Biotech, Pfizer Inc., Taj Pharmaceuticals Limited, CSL Limited, Novartis AG, Serum Institute of India. These key players are accomplishment moderately for removing the limitations by adopting the operative strategies & policies.
On the basis of disease indication, the Asia-Pacific conjugate vaccine market is segmented into pneumococcal, diphtheria tetanus pertussis (DTP), hemophilia influenza type B (Hib), meningococcal and others. Pneumococcus and Hibcause diseases containing infections such as pneumonia and meningitis. On the basis of the end-user, the market is segmented into adult and pediatric.
India is projected to designate the emergent market owing to the government’s focus on research and development (R&D) in the life sciences province. The Universal immunization program (UIP) offers Pneumococcal Conjugate Vaccine (PCV) to those who need most such as underserved and underprivileged people. Additionally, the major cause of bacterial meningitis is Hib. Hib is as a liquid pentavalent vaccine (LPV) collective with HepB in 10-dose and DPT. Moreover, the Ministry of Health and Family Welfare (MoHFW) and Government of India (GoI) lead the conjugate vaccines in several states.
In Japan, the National Immunization Program launched two vaccines: PCV–13 and PPSV–23 for the elderly (65 & above). These vaccines are available for the inhibition of Streptococcus pneumonia-related diseases.
The market of conjugate vaccine market is mainly driven by increasing geriatric population, followed by growing awareness about the convenience of a higher number of vaccines, growing disposable income, modernization of healthcare infrastructure, rising healthcare expenditure and growing medical tourism industry. Apart from advantages, some of the key challenges are accessibility & availability of conjugate vaccines in distant areas and high prevalence of chronic diseases etc.
It is expected that the conjugate vaccines market in Asia-Pacific to reach US$ 66.6 billion, at a CAGR of 23.5%, by 2023. In terms of volume, it is estimated to reach 6,883.5 million units, expanding at a CAGR of 21.8%. In the upcoming years, it is projected that the market to grow due to effective investment by the new entrants.
To know more, click on the link below:-
Ankur Gupta, Head Marketing & Communications